YuceBio appeared at the China Precision Medicine Conference and was awarded the "2020 Excellent Partner of the Union of Chinese Oncology Management".
12Month
YuceBio was listed in the "Top 50 of Innovative Biotechnology Enterprises (Leading Enterprises) in Guangdong-Hong Kong-Macao Greater Bay Area".
12Month
YuceBio was awarded the Council Member of Belt and Road Life Sciences Economy Alliance.
12Month
YuceBio was awarded the "2020 New Healthcare Power Company of China".
12Month
YuceBio unveiled its neoantigen tumor immunodiagnosis and treatment technology at the 2020 China Conference on Tumor Biomarkers (CCTB•Guangzhou•Chongqing).
12Month
YuceBio passed the CAP certification and was ranked among internationally authoritative clinical testing laboratories!
11Month
YuceBio was selected in the list of "2020 Top 20 High-Tech High-Growth Companies and Tomorrow Stars".
11Month
YuceBio debuted at the 2020 Shenzhen International Biotech and Health Industry Expo (Biotech Exhibition), empowering China's precision immunodiagnosis and treatment.
11Month
During the 2020 China Conference on Oncology (CCO), Wu Dongfang from YuceBio communicated with its chairperson about the cooperation between pharmaceutical enterprises.
11Month
YuceBio passed the 2020 CAP-CFDNA EQA with a full score.
10Month
China TMB standardization project was started and YuceBio helped to establish the Chinese standard of TMB.
10Month
YuceBio joined hands with PICI and CRI to conduct a study and the results were published in Cell.
9Month
YuceBio was selected as "China's Most Promising Molecular Diagnostic Company" by CB Insights.
9Month
2020 CSCO Annual Meeting｜Forsee the future•YuceBio Satellite Symposium "Clinical Testing Session" was held.
9Month
2020 CSCO Annual Meeting｜Forsee the future•YuceBio Satellite Symposium "Large Panel Registration Session" was held.
9Month
2020 CSCO Annual Meeting｜Forsee the future•YuceBio Satellite Symposium "Biomarker and New Drug R&D Session" was held.
9Month
YuceBio passed the 2020 CAP-NGSST EQA with a full score.
8Month
YuceBio completed nearly RMB 300 million in Series C financing to create an integrated solution for tumor precision immunodiagnosis and treatment.
8Month
YuceBio passed the NCCL 2020 EQA of National High-Throughput Sequencing Assay and Bioinformatics Analysis of Tumor Somatic Mutation with a full score.
8Month
Launched the enhanced YuceOne® Plus
8Month
Guests gathered to witness YuceBio's 5th Anniversary Celebration.
8Month
YuceBio passed the 2020 EQA of High-Throughput Sequencing Assay of ctDNA gene mutation with a full score.
8Month
YuceBio passed the CAP's EQA of multi-gene tumor testing with a full score.
7Month
Science and technology empower lung cancer management: YuceBio joined the "Cloud-Enabled Lung Cancer Care by Great Doctors".
6Month
YuceBio's study results were released on the AACR.
6Month
YuceBio launched its dedicated "Yuce Genuine" ｜Real-world Study Forum on Translational Medicine of Tumor Immunotherapy Biomarkers and held over ten forums online and offline throughout the year.
6Month
The Bioethics Committee of YuceBio was established.
4Month
YuceBio launched the "Genomics+ Program".
4Month
Became a collaborative partner of national TMB standard products and participated in the establishment of Chinese TMB standards.
4Month
Launched the online live streaming courses in spring 2020
4Month
Jie Lin, Party Secretary of the Shenzhen Committee of the Chinese People's Political Consultative Conference, led a team to visit YuceBio and guide the full resumption of work and production.
3Month
During the pandemic, all employees of YuceBio worked online, and senior executives held management meetings in various special ways.
2Month
YuceBio participated in the joint initiative of anti-epidemic and anti-virus actions.
12Month
In 2019, YuceBio's marketing revenue exceeded RMB 50 million.
12Month
YuceBio held more than 100 academic conferences, covering more than ten cities and regions including Beijing, Wuhan, Guangzhou, and Tianjin.
9Month
Cooperated with XBentury on the innovative exploration of artificial intelligence in the field of tumor immunodiagnosis.
9Month
Joined hands with MGI to promote the standardization of tumor immunodiagnosis and treatment.
9Month
YuceBio appeared at CSCO Annual Meeting and held a pre-conference meeting with the theme of "Comprehensive Evaluation, Leading the Future".
4Month
YuceBio's study results were released on the AACR.
1Month
Started the large panel certification work, and YuceMed's GMP plant was built in China Medical City in Taizhou
1Month
The personalized vaccine cooperation project based on tumor neoantigens was selected as one of the Top Ten Advances in China's Pharmaceutical Biotechnology in 2018.
11Month
Dr. Gao Zhibo delivered a keynote speech at the 2018 NeoAg Summit, sharing the experience in neoantigen studies in China.
11Month
Visited the Parker Institute for Cancer Immunotherapy (an initiator of the TESLA) (Boston, USA)
11Month
Received nearly RMB 100 million in Series B financing led by IDG, a well-known international venture capital institution
9Month
YuceBio participated in the 21st CSCO Annual Meeting and won the second place in the Best Satellite Symposium of the Genetic Testing Group (Xiamen, China).
5Month
Established the subsidiary Shenzhen Yuce Neoantigen Technology Co., Ltd. to carry out CDMO services for neoantigen assay, synthesis and validation
3Month
Announced the results of the first anniversary of the "Ladder for Cancer Moonshot" (YuceBio Satellite Symposium on the 2nd CSCO Cancer Immunotherapy Seminar, Chongqing, China)
12Month
Unveiled the YuceLab (International Bio-Valley, Dapeng, Shenzhen)
11Month
Proposed dual development strategies on neoantigen-based tumor immunodiagnosis and new therapies
10Month
Received nearly RMB 30 million in Series A financing from Puhua Capital and Miracle Light
9Month
Debuted for the first time at the CSCO (Chinese Society of Clinical Oncology) Annual Meeting and became a CSCO member.
6Month
Became a member of the Genomics Industry Alliance and participated in the Gene Industry Innovation and Entrepreneurship Summit
6Month
Became the first Chinese company to join the Tumor Neoantigen Selection Alliance (TESLA)
4Month
Jointly carried out the first clinical study of a new neoantigen-based
3Month
YuceBio launched the "Ladder for Cancer Moonshot".
10Month
YuceBio's first market event was unveiled at the 2016 International Academic and Industrial Forum of Precision Medicine (Shanghai, China).
6Month
Received nearly RMB 10 million in angel round financing from BioClub
10Month
Developed the high-quality neoantigen assay technology TruNeo™ 1.0, and launched the neoantigen assay technology service
